REGENXBIO’s $1.8 Billion Partnership With AbbVie

McDermott Will & Emery represented REGENXBIO in the transaction.

REGENXBIO closed its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. 

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. 

The McDermott team was led by Krist Werling (Picture) and included Rich Smith, Monika Richter, Andrea Hamilton and Becky DuFur. Tom Conaghan is the relationship partner for REGENXBIO.

Involved fees earner: Thomas Conaghan – McDermott Will & Emery; Rebecca Dufur – McDermott Will & Emery; Andrea Hamilton – McDermott Will & Emery; Monika Emilia Richter – McDermott Will & Emery; Rich Smith – McDermott Will & Emery; Kristian Werling – McDermott Will & Emery;

Law Firms: McDermott Will & Emery;

Clients: REGENXBIO Inc.;

Author: Martina Bellini